« Return to News | CROs/Service Providers

Quintiles launches Allume support services

Friday, July 13, 2012 03:19 PM

Quintiles has introduced Allume, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume simplifies and organizes the complex and resource-intensive launch planning process, provides unique data-driven insights from market-entry experience across the globe and taps Quintiles’ local market and therapeutic category expertise.

“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, vice president, consulting, at Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets.”

Allume combines consulting, clinical and commercial expertise with with state-of-the-art software, incorporating Quintiles’ biopharma product launch experience into support to complement in-house capabilities. It can be customized to each company and product to help identify key market challenges, fast-track launch rollout and efficiency in resource management.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.